m-lab is committed to commercialize a Glaucoma diagnostic lateral flow platform using tear fluid that will provide the general population easy and affordable access to disease detection. We foresee a yearly test at below €20 for all people aged over 50 years.

The test is based on a highly sensitive multiplexing LFT platform detecting disease specific marker patterns in tear fluid with a reader and software for A.I. disease scoring.

In parallel, we are continuously developing our therapeutic antibody program, with the aim of developing urgently needed new treatment options .
We are now looking for the next financial round.

If you are beside of glaucoma interested in:

• using the m-lab proprietary technology for multiplexing lateral flow assays
• a LFT for monitoring covid vaccination protection (on the market in Japan)
• OEM manufacturing of LFT
• Developing and consulting in diagnostic developments
• Diagnostic and therapeutic developments in other eye diseases like AMD
  please contact us!